Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER)
Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER)
复制标题
DOI：
10.1016/j.jjcc.2016.05.002
复制
发表时间：
2017-03-01
影响因子：
2.5
通讯作者：
Hagiwara, Nobuhisa
中科院分区：
文献类型：
--
作者：
Kawada-Watanabe, Erisa;Ogawa, Hiroshi;Hagiwara, Nobuhisa
背景：与西方国家目前的指南相反，日本建议动脉粥样硬化性心血管疾病和血脂异常患者即使在二级预防中也要适度降低低密度脂蛋白胆固醇（LDL-C）。HIJ-PROPER（日本心脏研究所）是一项前瞻性、随机、开放标签、盲法终点多中心试验，旨在评估标准剂量的他汀类药物加依折替米贝是否能密切控制LDL-C的降低
Background: In contrast to current guidelines in Western countries, moderate reduction of low-density lipoprotein cholesterol (LDL-C) is recommended for Japanese patients with atherosclerotic cardiovascular disease and dyslipidemia even in secondary prevention. HIJ-PROPER (Heart Institute of Japan-PRoper level of lipid lowering with Pitavastatin and Ezetimibe in acute coRonary syndrome) is a prospective, randomized, open-label, blinded endpoint multicenter trial designed to assess whether closely controlled LDL-C lowering with a standard statin dose plus ezetimibe, targeting LDL-C of